We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
本期《行业之声》想要着重强调在任何药物研究过程中的一个主要领域。生物统计学涉及临床研究的每个步骤，如试验设计、方案制定、数据管理和临床试验报告。这次我们的嘉宾是OCT Clinical公司的生物统计学主管Kristina Bondareva。她将分享她对生物统计学总体作用的看法，并对EMA采用“临床试验中的估计目标与敏感性分析(E9指导原则增补文件)”发表相关评论。
想要了解更多该话题的相关资讯，请观看“ICH E9(R1) ：临床试验中的估计目标与敏感性分析(E9指导原则增补文件)”的网络研讨会。
To learn more on the topic watch a webinar on the ICH E9(R1) Addendum on Estimands and Sensitivity Analysis.
 ：临床试验中的估计目标与敏感性分析(E9指导原则增补文件)&p%5Bsummary%5D=DESC&p%5Burl%5D=https://oct-clinicaltrials.com/cn/resources/oct-tv/industry-voice-14-ich-e9-r1-addendum-on-estimands-and-sensitivity-analysis&p%5Bimages%5D%5B0%5D=https://oct-clinicaltrials.com/cn/assets/images/1365/1365-j9bgfx-IV_14_News_Cover.jpg)
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
